Back to Search
Start Over
Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.
- Source :
-
Journal of diabetes research [J Diabetes Res] 2015; Vol. 2015, pp. 157698. Date of Electronic Publication: 2015 Apr 28. - Publication Year :
- 2015
-
Abstract
- Background: Type 2 diabetes (T2DM) patients, including those in good glycemic control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control may reduce long-term CVD risk. However, other risk factors such as elevated vascular sympathetic tone and/or endothelial dysfunction may be stronger potentiators of CVD. This study evaluated the impact of bromocriptine-QR, a sympatholytic dopamine D2 receptor agonist, on progression of metabolic disease and CVD in T2DM subjects in good glycemic control (HbA1c ≤ 7.0%).<br />Methods: 1834 subjects (1219 bromocriptine-QR; 615 placebo) with baseline HbA1c ≤ 7.0% derived from the Cycloset Safety Trial (this trial is registered with ClinicalTrials.gov Identifier: NCT00377676), a 12-month, randomized, multicenter, placebo-controlled, double-blind study in T2DM, were evaluated. Treatment impact upon a prespecified composite CVD endpoint (first myocardial infarction, stroke, coronary revascularization, or hospitalization for angina/congestive heart failure) and the odds of losing glycemic control (HbA1c >7.0% after 52 weeks of therapy) were determined.<br />Results: Bromocriptine-QR reduced the CVD endpoint by 48% (intention-to-treat; HR: 0.52 [0.28-0.98]) and 52% (on-treatment analysis; HR: 0.48 [0.24-0.95]). Bromocriptine-QR also reduced the odds of both losing glycemic control (OR: 0.63 (0.47-0.85), p = 0.002) and requiring treatment intensification to maintain HbA1c ≤ 7.0% (OR: 0.46 (0.31-0.69), p = 0.0002).<br />Conclusions: Bromocriptine-QR therapy slowed the progression of CVD and metabolic disease in T2DM subjects in good glycemic control.
- Subjects :
- Aged
Blood Glucose analysis
Bromocriptine administration & dosage
Cardiovascular Diseases etiology
Delayed-Action Preparations
Diabetes Mellitus, Type 2 drug therapy
Disease Progression
Dopamine Agonists administration & dosage
Double-Blind Method
Female
Humans
Hyperglycemia complications
Hypoglycemic Agents therapeutic use
Male
Middle Aged
Treatment Outcome
Bromocriptine therapeutic use
Cardiovascular Diseases drug therapy
Diabetes Mellitus, Type 2 complications
Dopamine Agonists therapeutic use
Hyperglycemia drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 2314-6753
- Volume :
- 2015
- Database :
- MEDLINE
- Journal :
- Journal of diabetes research
- Publication Type :
- Academic Journal
- Accession number :
- 26060823
- Full Text :
- https://doi.org/10.1155/2015/157698